Search results

Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

Result type

Technology appraisal guidance

Published

6 February 2018

Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.

Result type

Technology appraisal guidance

Published

27 January 2016

In development Reference number: GID-TA11552 Expected publication date:  25 September 2026

Result type

Technology appraisal guidance

Status

In development

Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.

Result type

Technology appraisal guidance

Published

1 February 2023

This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.

Result type

Clinical guideline

Last updated

23 May 2017

Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

Result type

Technology appraisal guidance

Published

17 November 2021

This guidance has been updated and replaced by NICE technology appraisal guidance 504.

Result type

Technology appraisal guidance

Published

24 April 2013

Past technology appraisal appeals and decisions